We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Eflornithine

By: Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC

Published In: Voice

Publication Date: 2024-05-21

Description

Eflornithine (Iwilfin^™) is the first U.S. Food and Drug Administration–approved oral maintenance therapy for high-risk neuroblastoma. Approved in December 2023, eflornithine has an orphan drug designation.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Eflornithine

Description

ONS Drug Education

Related Topics